| Literature DB >> 28474991 |
Daiki Murata1, Yohei Mineharu1, Yoshiki Arakawa1, Bin Liu1, Masahiro Tanji1, Makoto Yamaguchi1, Ko-Ichi Fujimoto1, Nobuyuki Fukui1, Yukinori Terada1, Ryuta Yokogawa1, Maki Yamaguchi2, Sachiko Minamiguchi2, Susumu Miyamoto1.
Abstract
OBJECTIVE Medulloblastoma is a type of malignant tumor arising in the cerebellum. The clinical importance of programmed cell death 1 ligand-1 (PD-L1) expression in medulloblastoma remains unknown. The aim of the present study was to examine the expression of PD-L1 and tumor-infiltrating T cells, and to evaluate their relationships to the prognosis of patients with medulloblastoma. METHODS The authors immunohistochemically analyzed PD-L1 expression and CD3+ and CD8+ lymphocyte infiltrations in tumor specimens from 16 patients with medulloblastoma. RESULTS High expression of PD-L1 was observed in 9 (56.3%) of 16 samples studied. High expression of PD-L1 was associated with low infiltrations of CD3+ or CD8+ lymphocytes. Patients with high expression of PD-L1 had shorter progression-free survival and overall survival times than those with low expression (p = 0.076 and p = 0.099, respectively). In addition, patients with high expression of PD-L1 and with low infiltration of CD8+ lymphocytes had a significantly worse outcome, with a 5-year survival rate of 15%, as compared with the other patients, who had a 5-year survival rate of nearly 90% (p = 0.0048 for progression-free survival and p = 0.010 for overall survival). CONCLUSIONS These findings indicate that PD-L1 expression was associated with a reduced infiltration of CD8+ T cells and poor prognosis in human medulloblastoma.Entities:
Keywords: OS = overall survival; PD-L1; PD-L1 = programmed cell death 1 ligand–1; PFS = progression-free survival; antitumor immunity; lymphocyte; medulloblastoma; oncology; prognosis; programmed cell death 1 ligand–1
Mesh:
Substances:
Year: 2017 PMID: 28474991 DOI: 10.3171/2016.11.JNS16991
Source DB: PubMed Journal: J Neurosurg ISSN: 0022-3085 Impact factor: 5.115